Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Up 16.4% in December

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 57,600 shares, a growth of 16.4% from the November 30th total of 49,500 shares. Based on an average trading volume of 170,100 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.9% of the shares of the stock are sold short.

Adial Pharmaceuticals Stock Performance

ADIL stock opened at $1.02 on Monday. Adial Pharmaceuticals has a 1 year low of $0.77 and a 1 year high of $4.17. The business has a 50 day simple moving average of $1.06 and a 200-day simple moving average of $1.05.

Analyst Upgrades and Downgrades

ADIL has been the topic of a number of research analyst reports. Rodman & Renshaw initiated coverage on Adial Pharmaceuticals in a research note on Thursday, November 14th. They issued a “buy” rating and a $8.00 price target on the stock. RODMAN&RENSHAW upgraded shares of Adial Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, November 14th.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.